Cancer Centers Renew and Expand BioDiscovery's Nexus Copy Number Software Licenses

Share Article

Leading cancer centers including Fox Chase Cancer Center's Keystone Program in Blood Cell Development and Cancer, the City of Hope Comprehensive Cancer Center, and the National Cancer Institute renew and expand licenses to BioDiscovery's Nexus Copy Number software.

BioDiscovery, Inc. a global leader in integrated software solutions for microarray-based research, announced today a number of license renewals and expansions of its Nexus Copy Number product at leading cancer research centers. These include renewal of multi-user license at the Fox Chase Cancer Center's Keystone Program in Blood Cell Development and Cancer, renewal and expansion at the City of Hope Comprehensive Cancer Center, and renewal and expansion at the National Cancer Institute. Since its launch over two years ago, Nexus Copy Number has quickly evolved into one of the most popular and widely used commercial software tools for detection of copy number aberrations from aCGH and SNP arrays as well as statistical analysis of large cohorts of samples. One of its largest groups of users and early adopters has been the cancer research community.

"We are very excited to see a rapid and steady growth in our user base from major cancer centers across the globe," said Dr. Soheil Shams, President of BioDiscovery. "It is especially important to us to see that Nexus Copy Number has enabled scientist to reduce the analysis time from several months or even years down to a few hours allowing them to make the most of their valuable data which eventually benefits finding a cure for this important disease."

Nexus Copy Number was designed specifically for researchers and users find it to be exceptionally easy to use. The software's flexibility in allowing different algorithms, custom annotation tracks, capacity to process thousands of arrays from any manufacturer in one project and numerous other features have set Nexus apart from other software packages. These research results have generated a number of recent publications in high impact journals such as Science and Nature.

About BioDiscovery, Inc.
BioDiscovery is a leader in the development of microarray advanced bioinformatics software and services that enable its customers to revolutionize drug discovery and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray and Next-Gen sequencing technology. Contact BioDiscovery: 310-414-8100 or

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Soheil Shams
Visit website